Free Trial

Labcorp (NYSE:LH) Rating Lowered to Hold at HSBC

Labcorp logo with Medical background

HSBC downgraded shares of Labcorp (NYSE:LH - Free Report) from a buy rating to a hold rating in a research report released on Thursday, Marketbeat Ratings reports. They currently have $260.00 price target on the medical research company's stock.

Other equities research analysts have also recently issued reports about the company. Robert W. Baird upped their price target on Labcorp from $253.00 to $267.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 30th. Wall Street Zen cut Labcorp from a "buy" rating to a "hold" rating in a research note on Friday, April 18th. Barclays reissued a "cautious" rating on shares of Labcorp in a research note on Wednesday, June 25th. Morgan Stanley increased their target price on Labcorp from $270.00 to $283.00 and gave the stock an "overweight" rating in a research note on Wednesday, June 11th. Finally, Piper Sandler reissued a "neutral" rating and issued a $280.00 target price (up from $260.00) on shares of Labcorp in a research note on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $276.38.

Check Out Our Latest Report on LH

Labcorp Price Performance

NYSE:LH traded down $5.90 during mid-day trading on Thursday, reaching $253.17. The stock had a trading volume of 1,375,796 shares, compared to its average volume of 646,170. The firm has a 50 day moving average price of $253.38 and a two-hundred day moving average price of $242.78. The stock has a market capitalization of $21.19 billion, a P/E ratio of 29.27, a P/E/G ratio of 1.64 and a beta of 0.82. Labcorp has a one year low of $200.90 and a one year high of $265.72. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.60 and a current ratio of 1.84.

Labcorp (NYSE:LH - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The medical research company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.73 by $0.11. Labcorp had a return on equity of 15.27% and a net margin of 5.55%. The firm had revenue of $3.35 billion during the quarter, compared to the consensus estimate of $3.41 billion. During the same quarter in the previous year, the company posted $3.68 earnings per share. The business's revenue was up 5.3% on a year-over-year basis. As a group, analysts expect that Labcorp will post 16.01 earnings per share for the current year.

Labcorp Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 11th. Stockholders of record on Thursday, August 28th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.14%. Labcorp's dividend payout ratio (DPR) is presently 33.29%.

Insider Buying and Selling

In related news, CEO Adam H. Schechter sold 6,105 shares of the company's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $248.73, for a total value of $1,518,496.65. Following the completion of the transaction, the chief executive officer owned 98,962 shares of the company's stock, valued at approximately $24,614,818.26. This represents a 5.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Peter J. Wilkinson sold 829 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $242.26, for a total value of $200,833.54. Following the sale, the chief accounting officer owned 2,054 shares of the company's stock, valued at approximately $497,602.04. This trade represents a 28.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,834 shares of company stock worth $2,928,714 in the last ninety days. 0.84% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Contravisory Investment Management Inc. boosted its stake in shares of Labcorp by 3,057.4% in the 2nd quarter. Contravisory Investment Management Inc. now owns 38,362 shares of the medical research company's stock valued at $10,070,000 after buying an additional 37,147 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Labcorp by 3.7% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 37,533 shares of the medical research company's stock valued at $9,830,000 after buying an additional 1,351 shares during the period. Strathmore Capital Advisors Inc. purchased a new position in shares of Labcorp in the 2nd quarter valued at about $713,000. Longboard Asset Management LP purchased a new position in shares of Labcorp in the 2nd quarter valued at about $201,000. Finally, Atticus Wealth Management LLC boosted its stake in shares of Labcorp by 119.2% in the 2nd quarter. Atticus Wealth Management LLC now owns 605 shares of the medical research company's stock valued at $159,000 after buying an additional 329 shares during the period. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Labcorp Company Profile

(Get Free Report)

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

Featured Stories

Analyst Recommendations for Labcorp (NYSE:LH)

Should You Invest $1,000 in Labcorp Right Now?

Before you consider Labcorp, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Labcorp wasn't on the list.

While Labcorp currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Top 3 Defense Stocks to Profit From $175 Billion Golden Dome

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines